Drug profile · INN
imatinib mesylate
IMATINIB MESYLATE
imatinib mesylate (IMATINIB MESYLATE) is a platelet-derived growth factor receptor beta inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — imatinib mesylate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 9
- Programs
- 8
- Data quality
- 0.89
Quick answer
imatinib mesylate (IMATINIB MESYLATE) is a platelet-derived growth factor receptor beta inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Platelet-derived growth factor receptor beta inhibitor
Primary target: Bcr/Abl fusion protein
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 11725005
Compositions and methods for inhibiting kinases
granted -
US 11407747
Compositions and methods for inhibiting kinases
granted -
US 10906896
Compositions and methods for inhibiting kinases
granted -
US 10344027
Compositions and methods for inhibiting kinases
granted -
US 10316031
Compositions and methods for inhibiting kinases
granted -
US 10118923
Compositions and methods for inhibiting kinases
granted -
US 9907796
Methods of treating tumoral diseases, or bacterial or viral infections
granted -
US 9828370
Compositions and methods for inhibiting kinases
granted -
US 9487500
Compounds and compositions thereof
granted
Frequently asked questions
What is imatinib mesylate?
imatinib mesylate (IMATINIB MESYLATE) is a platelet-derived growth factor receptor beta inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for imatinib mesylate?
IMATINIB MESYLATE is a marketed brand name for imatinib mesylate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of imatinib mesylate?
imatinib mesylate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.